Madrigal Pharmaceuticals (MDGL) Peer Comparison
$427.39
As on 13-Nov-2026 16:01EST
Market cap
$9,928 Mln
Revenue (TTM)
$1,428 Mln
P/E Ratio
--
P/B Ratio
15.8
Div. Yield
0 %
| Madrigal Pharmaceuticals (MDGL) | Exelixis (EXEL) | Ascendis Pharma A/S - ADR | Halozyme Therapeutics (HALO) | Kymera Therapeutics (KYMR) | |
|---|---|---|---|---|---|
Market cap ($ Mln) |
9,928 | 16,837 | 18,064 | 11,432 | 10,891 |
Revenue ($ Mln) |
1,428 | 2,497 | 1,208 | 1,802 | 102 |
Net Profit ($ Mln) |
-155.46 | 885.14 | 890.37 | 485.42 | -349.47 |
Net Margin (%) |
-10.89 | 35.45 | 73.69 | 26.93 | -341.87 |
RoE (%) |
-26.57 | 46.96 | 88.40 | -- | -22.16 |
Price to Earnings |
-- | 20.66 | 18.11 | 25.19 | -- |
Price-To-Book |
15.76 | 9.18 | 10.44 | 97.15 | 6.72 |
Income Statement ($ Mln)
| Madrigal Pharmaceuticals (MDGL) | Exelixis (EXEL) | Ascendis Pharma A/S - ADR | Halozyme Therapeutics (HALO) | Kymera Therapeutics (KYMR) | |
|---|---|---|---|---|---|
|
Operating Revenue
|
1,427.94 | 2,496.86 | 1,208.20 | 1,802.45 | 102.23 |
|
Cost of Revenue
|
129.12 | 93.32 | 113.42 | 319.65 | -74.16 |
|
Gross Profit
|
902.26 | 2,236.43 | 588.53 | 1,167.84 | 39.20 |
|
Operating Expenses
|
1,451.47 | 1,400.14 | 872.49 | 474.96 | 583.29 |
|
Operating Profit (EBIT)
|
-152.65 | 1,003.39 | 222.29 | 1,007.84 | -404.89 |
|
Other Income
|
0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
|
Profit before Tax
|
-155.46 | 1,065.84 | 271.18 | 655.01 | -349.70 |
|
Provision for Tax
|
0.00 | 180.70 | -619.19 | 169.59 | 0.00 |
|
Profit after Tax (Net Income)
|
-155.46 | 885.14 | 890.37 | 485.42 | -349.47 |
|
Minority Interest
|
0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
|
Consolidated Profit
|
0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Liabilities ($ Mln)
| Madrigal Pharmaceuticals (MDGL) | Exelixis (EXEL) | Ascendis Pharma A/S - ADR | Halozyme Therapeutics (HALO) | Kymera Therapeutics (KYMR) | |
|---|---|---|---|---|---|
|
Shareholder's Funds
|
626.94 | 1,833.83 | 1,525.85 | -55.24 | 1,614.53 |
|
Minority Interest
|
0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
|
Non-Current Liabilities
|
353.20 | 267.78 | 384.05 | 3,052.50 | 63.02 |
|
Current Liabilities
|
454.24 | 411.88 | 558.37 | 476.09 | 89.72 |
|
Total Liabilities
|
1,259.59 | 2,844.42 | 1,302.02 | 2,525.32 | 1,742.81 |
Assets ($ Mln)
| Madrigal Pharmaceuticals (MDGL) | Exelixis (EXEL) | Ascendis Pharma A/S - ADR | Halozyme Therapeutics (HALO) | Kymera Therapeutics (KYMR) | |
|---|---|---|---|---|---|
|
Non-Current Assets
|
47.28 | 1,191.87 | 854.45 | 1,626.62 | 768.68 |
|
Current Assets
|
1,387.11 | 1,321.62 | 1,613.82 | 1,846.73 | 998.59 |
|
Total Assets
|
1,259.59 | 2,844.42 | 1,302.02 | 2,525.32 | 1,742.81 |
|
Total Debt*
|
354.22 | 162.20 | 455.38 | 3,250.30 | 76.60 |
|
Net Current Assets
|
932.87 | 909.75 | 1,037.87 | 1,370.64 | 908.87 |
Cashflow ($ Mln)
| Madrigal Pharmaceuticals (MDGL) | Exelixis (EXEL) | Ascendis Pharma A/S - ADR | Halozyme Therapeutics (HALO) | Kymera Therapeutics (KYMR) | |
|---|---|---|---|---|---|
|
Cash From Operating Activities
|
-189.55 | 884.27 | 51.77 | 651.56 | -232.89 |
|
Cash Flow from Investing Activities
|
32.32 | 350.44 | -8.15 | -545.81 | -521.06 |
|
Cash from Financing Activities
|
255.98 | -969.59 | 34.89 | -85.17 | 990.71 |
|
Net Cash Inflow / Outflow
|
-- | -- | -- | -- | -- |
Ratios
Profitability Ratios
| Madrigal Pharmaceuticals (MDGL) | Exelixis (EXEL) | Ascendis Pharma A/S - ADR | Halozyme Therapeutics (HALO) | Kymera Therapeutics (KYMR) | |
|---|---|---|---|---|---|
|
ROCE (%)
|
-31.49 | 32.82 | -30.01 | 15.61 | -24.09 |
|
ROE (%)
|
-26.57 | 46.96 | 88.40 | 153.59 | -22.16 |
|
ROA (%)
|
-8.54 | 28.91 | 34.34 | 13.85 | -23.06 |
|
EBIT Margin (%)
|
-8.64 | 42.02 | 20.00 | 37.56 | -341.82 |
|
Net Margin (%)
|
-10.89 | 35.45 | 73.69 | 26.93 | -341.87 |
|
Cash Profit Margin (%)
|
0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Growth Ratios
| Madrigal Pharmaceuticals (MDGL) | Exelixis (EXEL) | Ascendis Pharma A/S - ADR | Halozyme Therapeutics (HALO) | Kymera Therapeutics (KYMR) | |
|---|---|---|---|---|---|
|
Revenue Growth (%)
|
92.80 | 9.12 | 86.87 | 45.03 | 133.74 |
|
EBIT Growth (%)
|
54.59 | 23.13 | 260.53 | -11.34 | -18.50 |
|
Net Profit Growth (%)
|
46.23 | 30.57 | 482.23 | -18.48 | -18.42 |
|
EPS Growth (%)
|
53.71 | 38.78 | 453.25 | -17.34 | -2.42 |
|
Book Value Growth (%)
|
-25.69 | -7.57 | 878.06 | -110.94 | 48.81 |
Valuation Ratios
| Madrigal Pharmaceuticals (MDGL) | Exelixis (EXEL) | Ascendis Pharma A/S - ADR | Halozyme Therapeutics (HALO) | Kymera Therapeutics (KYMR) | |
|---|---|---|---|---|---|
|
Price / Earnings
|
-45.32 | 15.79 | -59.76 | 24.99 | -21.09 |
|
Price / Book Value
|
15.76 | 9.18 | 10.44 | 97.15 | 6.72 |
|
Dividend Yield (%)
|
0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
|
EV/EBITDA
|
-76.35 | 14.81 | 70.48 | 16.67 | -29.66 |
|
Market Cap ($ Cr)
|
-- | -- | -- | -- | -- |
Solvency Ratios
| Madrigal Pharmaceuticals (MDGL) | Exelixis (EXEL) | Ascendis Pharma A/S - ADR | Halozyme Therapeutics (HALO) | Kymera Therapeutics (KYMR) | |
|---|---|---|---|---|---|
|
Debt to Equity
|
0.54 | 0.00 | 0.25 | -53.31 | 0.00 |
|
Short term debt to equity ratio
|
0.00 | 0.00 | 0.05 | -5.53 | 0.01 |
|
Current Ratio
|
3.05 | 3.21 | 2.89 | 3.88 | 11.13 |
|
Quick Ratio
|
2.78 | 3.14 | 2.29 | 3.60 | 11.13 |
|
Interest Coverage
|
-3.84 | -- | 2.74 | 30.70 | -1,279.94 |
Operating Efficiency Ratios
| Madrigal Pharmaceuticals (MDGL) | Exelixis (EXEL) | Ascendis Pharma A/S - ADR | Halozyme Therapeutics (HALO) | Kymera Therapeutics (KYMR) | |
|---|---|---|---|---|---|
|
Debtors to sales (%)
|
15.92 | 13.16 | 21.41 | 29.16 | 0.00 |
|
Asset Turnover
|
0.78 | 0.82 | 0.47 | 0.51 | 0.07 |
|
Receivable days
|
35.88 | 43.48 | 85.52 | 98.04 | 8.82 |
|
Inventory Days
|
354.23 | 96.17 | 1,056.70 | 254.12 | -- |
|
Payable days
|
300.79 | 147.97 | 331.01 | 24.86 | -- |
|
Cash Conversion Cycle
|
89.33 | -8.32 | 811.21 | 327.29 | -- |